Literature DB >> 23833177

Immunomodulatory effects of antileishmanial drugs.

Moumita Ghosh1, Koushik Roy, Syamal Roy.   

Abstract

OBJECTIVES: The commonly used antileishmanial drugs are sodium antimony gluconate (SAG), amphotericin B, miltefosine and paromomycin. There are a number of reports that antileishmanial drugs show immunomodulatory properties. Here, we attempt to understand how the innate arm of the immune system is modulated in response to these antileishmanial drugs.
METHODS: BALB/c peritoneal macrophages were treated with miltefosine, SAG, amphotericin B or paromomycin. The membrane fluidity of macrophages following drug treatment was studied in terms of fluorescence anisotropy. The T cell-stimulating ability, production of cytokines and nitrogen and oxygen metabolite production in drug-treated macrophages were also studied. The study was also carried out using peritoneal macrophages from drug-treated BALB/c mice.
RESULTS: The antileishmanial drugs altered macrophage membrane fluidity, except amphotericin B. The drug-treated macrophages showed enhanced T cell-stimulating ability and generation of reactive oxygen species, nitrite, interleukin-12 and tumour necrosis factor-α.
CONCLUSIONS: Antileishmanial drugs can stimulate the innate arm of the immune system, which may have a significant bearing on the cellular arm of the immune system.

Entities:  

Keywords:  SAG; amphotericin B; anisotropy; antigen presentation; immunomodulation; miltefosine; paromomycin

Mesh:

Substances:

Year:  2013        PMID: 23833177     DOI: 10.1093/jac/dkt262

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy.

Authors:  Julián Ernesto Nicolás Gulin; Margarita María Catalina Bisio; Daniela Rocco; Jaime Altcheh; María Elisa Solana; Facundo García-Bournissen
Journal:  Front Cell Infect Microbiol       Date:  2022-07-05       Impact factor: 6.073

2.  Pentalinon andrieuxii root extract is effective in the topical treatment of cutaneous leishmaniasis caused by Leishmania mexicana.

Authors:  Claudio M Lezama-Dávila; Li Pan; Angelica P Isaac-Márquez; Cesar Terrazas; Steve Oghumu; Ricardo Isaac-Márquez; M Y Pech-Dzib; Joseph Barbi; Edward Calomeni; Narasimham Parinandi; A Douglas Kinghorn; Abhay R Satoskar
Journal:  Phytother Res       Date:  2013-11-08       Impact factor: 5.878

3.  Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB).

Authors:  Rebuma Firdessa; Liam Good; Maria Cecilia Amstalden; Kantaraja Chindera; Nor Fadhilah Kamaruzzaman; Martina Schultheis; Bianca Röger; Nina Hecht; Tobias A Oelschlaeger; Lorenz Meinel; Tessa Lühmann; Heidrun Moll
Journal:  PLoS Negl Trop Dis       Date:  2015-10-02

4.  Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.

Authors:  Semra Palić; Patrick Bhairosing; Jos H Beijnen; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 5.  Precision Medicine in Control of Visceral Leishmaniasis Caused by L. donovani.

Authors:  Eduard E Zijlstra
Journal:  Front Cell Infect Microbiol       Date:  2021-11-09       Impact factor: 5.293

6.  A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions.

Authors:  Fariba Jaffary; Mohammad Ali Nilforoushzadeh; Amirhossein Siadat; Elaheh Haftbaradaran; Nazli Ansari; Elham Ahmadi
Journal:  Dermatol Res Pract       Date:  2016-04-11

7.  In vivo/In vitro immune responses to L. major isolates from patients with no clinical response to Glucantime.

Authors:  Sedigheh Saberi; Reza Arjmand; Simindokht Soleimanifard; Ali Khamesipour; Seyed Mohsen Hosseini; Mansoor Salehi; Jaleh Varshosaz; Abbas Ali Palizban; Seyed Hossein Hejazi
Journal:  Adv Biomed Res       Date:  2016-07-29

Review 8.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

Review 9.  Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria.

Authors:  María Álvarez-Bardón; Yolanda Pérez-Pertejo; César Ordóñez; Daniel Sepúlveda-Crespo; Nestor M Carballeira; Babu L Tekwani; Sankaranarayanan Murugesan; Maria Martinez-Valladares; Carlos García-Estrada; Rosa M Reguera; Rafael Balaña-Fouce
Journal:  Mar Drugs       Date:  2020-03-31       Impact factor: 5.118

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.